OAM
AKTX

Oxford Asset Management’s Akari Therapeutics AKTX Stock Holding History

Oxford Asset Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13
Closed -$18K – 250
2019
Q4 		$18K Buy
+13
New +$19.2K ﹤0.01% 1696
2018
Q1 		– Sell
-45
Closed -$159K – 1578
2017
Q4 		$159K Buy
+45
New +$174K ﹤0.01% 1485

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OFW
Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PCG
Private Capital Group West Hartford, Connecticut $133M AUM 11.23% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Oxford Asset Management's AKTX Position: Q1 2020 in Review

Oxford Asset Management sold out of Akari Therapeutics (AKTX) in Q1 2020, closing a stake of 13 shares — an estimated $18K sold.

Oxford Asset Management first reported a position in AKTX in Q4 2017 and held it in 2 quarters. The position peaked at $159K in Q4 2017. 12 funds tracked by Wall St. Rank hold AKTX as of Q1 2020.

  • Oxford Asset Management reported no remaining Akari Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 13 Akari Therapeutics shares in Q1 2020, an estimated $18K.
  • Oxford Asset Management first reported a position in Akari Therapeutics in Q4 2017 and held it in 2 quarters.
  • Oxford Asset Management's Akari Therapeutics position peaked at $159K in Q4 2017.
  • 12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.